Filing Details

Accession Number:
0001140361-13-034587
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-08-29 16:35:27
Reporting Period:
2013-08-27
Filing Date:
2013-08-29
Accepted Time:
2013-08-29 16:35:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1311596 Regado Biosciences Inc RGDO Pharmaceutical Preparations (2834) 030422069
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1170144 Quaker Bio Ventures Lp C/o Cira Centre
2929 Arch Street
Philadelphia PA 19104
No No Yes No
1223034 Quaker Bioventures Capital Lp 435 Dover Park Drive
Bldg 500
Wayne PA 19087
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Acquisiton 2013-08-27 399,201 $0.00 435,129 No 4 C Direct
Common Stock, Par Value $0.001 Per Share Acquisiton 2013-08-27 273,468 $0.00 708,597 No 4 C Direct
Common Stock, Par Value $0.001 Per Share Acquisiton 2013-08-27 465,252 $0.00 1,173,849 No 4 C Direct
Common Stock, Par Value $0.001 Per Share Acquisiton 2013-08-27 48,362 $0.00 1,222,211 No 4 C Direct
Common Stock, Par Value $0.001 Per Share Acquisiton 2013-08-27 71,810 $4.00 1,294,021 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, Par Value $0.001 Per Share Series B Preferred Stock Disposition 2013-08-27 6,666,667 $0.00 399,201 $0.00
Common Stock, Par Value $0.001 Per Share Series C Preferred Stock Disposition 2013-08-27 4,566,908 $0.00 273,468 $0.00
Common Stock, Par Value $0.001 Per Share Series D Preferred Stock Disposition 2013-08-27 7,769,715 $0.00 465,252 $0.00
Common Stock, Par Value $0.001 Per Share Series E Preferred Stock Disposition 2013-08-27 807,652 $0.00 48,362 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The reportable securities are directly held by Quaker BioVentures, L.P. (the "Reporting Person"). Quaker BioVentures Capital, L.P. ("Quaker Capital LP") is the general partner of the Quaker. Quaker BioVentures Capital, LLC ("Quaker Capital LLC") is the general partner of Quaker Capital LP and has voting and dispositive power over the shares held by the Reporting Person. Voting and investment determinations made by Quaker Capital LLC with respect to the shares held by the Reporting Person are made by an investment committee of Quaker Partners Management, L.P., which committee includes P. Sherrill Neff, a member of the board of the directors of the Company.
  2. The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
  3. The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
  4. The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
  5. The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.